ACEMg-mediated hearing preservation in cochlear implant patients receiving different electrode lengths (PROHEARING): study protocol for a randomized controlled trial by Scheper, Verena et al.
STUDY PROTOCOL Open Access
ACEMg-mediated hearing preservation in
cochlear implant patients receiving
different electrode lengths (PROHEARING):
study protocol for a randomized controlled
trial
Verena Scheper1,2*, Melanie Leifholz1, Heiko von der Leyen3, Miriam Keller3, Ute Denkena3, Armin Koch4,
Annika Karch4, Josef Miller5 and Thomas Lenarz1,2
Abstract
Background: The indications for a cochlear implant (CI) have been extended to include patients with some
residual hearing. Shorter and thinner atraumatic electrodes have been designed to preserve the residual hearing in
the implanted ear. However, the insertion of the electrode array into the cochlea, with potential mechanical trauma
and the presence of this foreign body inside the cochlea, may lead to free radical formation and reduced blood
perfusion of the cochlea which can result in the loss of residual hearing.
Methods/design: In this single-center, randomized, placebo-controlled, double-blind phase II clinical trial the effect
of free radical scavengers and a vasodilator on the residual hearing of 140 CI patients will be evaluated. The
formulation is composed of β-carotene (vitamin A), ascorbic acid (vitamin C), dl-α-tocopherol acetate (vitamin E)
and the vasodilator magnesium (Mg), or ACEMg. Medication is administered twice daily per os for approximately
3 months. The primary measure is based upon the reduction in postoperative low-frequency air-conducted pure-
tone thresholds compared to preoperative thresholds in ACEMg-treated patients compared to those of a placebo
group. Additionally, the effect of different electrode lengths (20, 24 and 28 mm) is analyzed. Study visits are
scheduled 2 days before surgery, at first fitting, which is the adjustment and start of stimulation via CI 4 weeks after
surgery and 3, 6, 9 and 12 months after first fitting. The primary endpoint is the air-conduction hearing loss at
500 Hz 3 months after first fitting. Additionally, speech recognition tests, hearing aid benefit in the implanted ear
and electrophysiological measurements of implant function are assessed.
Since this is a blinded clinical trial and recruitment is still ongoing, data continue to accrue and we cannot yet
analyze the outcome of the ACEMg treatment.
Discussion: There is an unfulfilled need for new strategies to preserve acoustic hearing in CI patients. This study
will provide first-in-man data on ACEMg-mediated protection of residual hearing in CI patients. Performing all
surgeries and patient follow-up at one study site improves consistency in diagnosis and therapy and less variability
in surgery, audiological test techniques and fitting. This approach will allow investigation of the influence of ACEMg
on residual hearing in CI patients.
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Background
The cochlear implant (CI) is the standard treatment for
unilateral and bilateral severe/profound hearing loss, both
in adults and children. The CI stimulates the auditory
nerve electrically through electrodes placed inside the
inner ear, the cochlea. Recently, as speech understanding
with the CI has improved, indication criteria have been
extended towards patients with more residual hearing. At
the same time, thinner and shorter atraumatic electrodes
have been designed to preserve the (low-frequency) re-
sidual hearing in the implanted ear [1, 2]. If hearing has
been preserved, then the electrical stimulation of the im-
plant may be combined with a hearing aid in the same ear
(electric acoustic stimulation, EAS).
The insertion of the electrode array into the cochlea
with potential mechanical trauma, and the chronic pres-
ence of this foreign body inside the cochlea may induce
loss of residual hearing. As Talbot and colleagues stated in
2004, a substantial acoustic hearing loss occurs in 24 % of
EAS CI patients, and among them 13 % show a total loss
of residual hearing [3]. More recent studies prove that the
occurring problem is not yet solved since a large number
of patients continue to suffer from partial or total loss of
residual hearing. In 15 % of patients analyzed by
Skarzynski a partial to total hearing loss was observed [4].
Other studies published a complete loss of residual hear-
ing in 22.7 % of subjects and a partial loss of hearing in
50.1 % of the total patient population (n = 22) [5] or a
mean threshold shift >15 dB 24 months after first fitting
(FF) in 41.2 % (Cochlear Implant Model Hybrid-L24, n =
51) and 71.4 % (Cochlear Implant Model CI422, n = 28),
respectively [6].
Experimental studies on the auditory system have dem-
onstrated that antioxidants plus a vasodilator reduce both
noise- and drug- (aminoglycoside)-induced inner ear
pathology and hearing loss by over 75 % [7]. This formula-
tion is β-carotene (converted in the body to vitamin A),
ascorbic acid (vitamin C), dl-α-tocopherol acetate (vitamin
E) and the vasodilator magnesium. Together (ACEMg)
they are remarkably effective in vivo. Data indicate that
free radicals play a key role in sensory and neural cell
death and loss of residual hearing with CI implantation [8,
9] which reduces the benefits of implantation. The goal of
ACEMg treatment is to eliminate one important contrib-
uting factor, the stress of surgery and implantation of a
foreign body that may reduce residual acoustic hearing in
the implanted patient.
Our PROHEARING clinical trial (PROtect residual
HEARING) is the first human trial to assess the efficacy of
ACEMg to prevent permanent hearing loss in CI patients
with residual hearing.
Methods/design
The PROHEARING trial is conducted in accordance
with the Declaration of Helsinki and complies with the
principles of Good Clinical Practice (GCP) and Good
Manufacturing Practice (GMP). The protocol is ap-
proved by the Independent Ethics Committee (IEC) of
Hannover Medical School (MHH) and by the national
legal authority, the Bundesinstitut für Arzneimittel und
Medizinprodukte (BfArM).
The trial is registered on the European Clinical Trials
Database (EudraCT Number: 2012-005002-22). It is
funded by a grant from the European Commission 7th
Framework Program in Public Health research. The trial
is being coordinated by the Clinic of Otorhinolaryngol-
ogy of MHH (sponsor). The MHH Institutes for Biostat-
istics and for Clinical Pharmacology support the trial
with their expertise and the Hannover Clinical Trial
Center (HCTC) is the management center of the study
and responsible for clinical monitoring and data man-
agement. The trial complies with the principles of GCP
and is carried out in accordance with applicable legisla-
tion and the Standard Operating Procedures of MHH.
The PROHEARING trial is a single-center, random-
ized, placebo-controlled, double-blind, phase II trial
including adults admitted to the MHH Department of
Otorhinolaryngology who are suffering from hearing
loss, have a defined level of residual hearing and receiv-
ing a cochlea implant.
The study has the primary objective to demonstrate
that ACEMg is more efficacious than placebo in preserv-
ing residual hearing during cochlear implantation by
comparing the hearing loss 3 months after FF at 500 Hz
in air-conducted pure-tone audiometry.
Key secondary objectives are:
 To investigate the drug effect over time (hearing loss
in ACEMg compared to placebo at 500 Hz 6, 9 and
12 months after FF)
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 To compare ACEMg and placebo for hearing loss at
different frequencies of pure-tone audiometry (125,
250 and 750 Hz, 1, 1.5, 2, 3, 4, 6 and 8 kHz) over
time (months 3, 6, 9 and 12 after FF)
 To compare efficacy by means of speech perception,
functional hearing and impedances
 To evaluate the effect of electrode length on hearing
loss
Inclusion and exclusion criteria
The patient must meet specific criteria during consult-
ation with the ENT surgeon before inclusion and
randomization. The appropriate examinations will be
performed to make sure that the patients meet the ex-
clusion and inclusion criteria. During the study, the pa-
tient has the right to leave the study at any time. If the
patient decides to stop the intake of the study medica-
tion he may continue the study and will be further
followed up.
Patients will be eligible for the trial if they fulfill all the
inclusion criteria (Table 1) and none of the exclusion cri-
teria (Table 2).
Blinding and randomization
This is a double-blind clinical trial. Patients fulfilling in-
clusion/exclusion criteria and giving written consent to
participate in this study are randomized 1:1 to ACEMg
or placebo. The randomization is stratified by the length
of the electrodes (short (16 and 20 mm) versus medium
(24 mm) versus long (28 mm)) as planned preoperatively
(albeit the length of the electrode is finally determined
during surgery). Randomization is performed centrally
using a web-based randomization tool. Randomization
lists are used to prepare blinded study treatments. The
manufacturer provides optically identical investigational
medicinal products (IMP) of ACEMg and placebo.
Sealed envelopes for emergency unblinding were pre-
pared prior to the study and handed out to the investiga-
tor. In addition to blinding patients and investigators,
the trial statisticians will stay blinded until the blind data
review is successfully completed.
Clinical outcome measures
The primary outcome of the PROHEARING trial will be
the hearing loss at the implanted ear at 500 Hz 3 months
post FF (hearing loss = 3 month post-FF threshold minus
1–2 days preoperative threshold) measured by air-
conducted pure-tone audiometry. Additionally, second-
ary endpoints are:
1. Hearing loss at the implanted ear measured by pure-
tone audiometry at 500 Hz 6, 9 and 12 months post FF
2. Hearing loss measured by pure-tone audiometry for
other frequencies (125 and 250 Hz, 1, 2 and 8 kHz)
over time (months 3, 6, 9 and 12 post FF)
3. Speech perception by the Oldenburger Satztest
(OLSA), month 12
4. Functional Hearing questionnaire NCIQ, months 3
and 12 after FF
5. Impedances (Ω) at all timepoints
Table 1 Inclusion criteria of the PROHEARING clinical trial
Inclusion criteria
1. 18 years of age or older
2. No or little benefit from a conventional hearing aid, defined as preoperative auditory speech understanding
of less or equal 60 % in Freiburger monosyllables at 65 dB SPL, best aided in the ear to be implanted
3. Residual hearing better or equal than 85 dB HL at 125, 90 dB HL at 250 Hz and better or equal than 95 dB
HL at 500 Hz in the ear to be implanted
4. Ability to understand the study procedures, possible risks and benefits, and to give informed consent
5. Informed Consent Document is signed.
6. Patients must agree not to use daily vitamin preparations containing vitamins A, C or E or magnesium during
the course of the study, and beginning at least 48 hours prior to first intake of the study medication
7. Female patients 50 years of age or older at the day of inclusion who have been postmenopausal for at least 1 year
Or
Female patients who have a negative hCG serum pregnancy test and meet one or more of the following criteria:
are 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral ovariectomy
with or without hysterectomy
are using proven oral, injected or implanted hormonal contraceptive methods:
intrauterine device or intrauterine system
barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide
(foam/gel/film/cream/suppository)
male sterilization (if the absence of sperm in the ejaculate is documented. For female participants the vasectomized
male partner should be the sole sexual partner for that subject)
true abstinence (periodic abstinence and coitus interruptus are not acceptable methods of contraception)
only female sexual partners
hCG human chorionic gonadotropin, HL hearing level, SPL sound pressure level
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6. Occurrence of tinnitus: Tinnitus Questionnaire at all
timepoints
Safety endpoints:
1. All serious adverse events (SAEs)
2. All adverse events (AEs) leading to discontinuation
of IMP intake
Investigational medicinal products
IMP Soundbites softgel capsules® and Soundbites® drug
information
In this study we supply a combination of vitamins A, C
and E together with magnesium, called Soundbites® (chew-
able pills) or Soundbites softgel capsules®, to CI patients
with residual hearing. The components of Soundbites® and
Soundbites softgel capsules® are listed in Table 3.
Due to their limited stability Soundbites® (chewing
pills) were used until 30 June 2015; thereafter, the dosage
form changed to Soundbites softgel capsules® with iden-
tical content of active substances.
The dosage of each of the nutrients was chosen to
maximize both safety and efficiency. The dosage of the
components are below the upper daily limits (UDL)
established by the EFSA (European Food Safety
Authority).
Treatment assignment
The study medication is administered only to patients
included in this study following the procedures set out
in the study protocol.
All patients who have signed an Informed Consent
Document are identified by a five-digit patient ID (i.e.,
01-001) that is generated by the electronic data capture
system and is used to identify the subject throughout the
study. The database stores only pseudonymized study
data. A particular web-based random tool is imple-
mented for this study into the environment of an elec-
tronic data capture system. Each member of the trial
staff is identified with a qualified account. The investiga-
tor supplies basic demographic and clinical details of the
patient and the patient is then allocated to one of the
treatments according to the stratified randomization list.
The investigator is informed of the blinded kit number
of the medication for the respective patient. Allocation
is split into two batches: a short-term kit for the pre-
operative treatment phase (medication for 14 days) and
a long-term kit for postoperative treatment (medication
for 91 days). All patients are only randomized once, but
kit numbers are generated on the day of inclusion for
the short-term kit (e.g., labels 0001, 0002, 0003, etc.) and
generally 1 day before surgery for the long-term kit (e.g.,
labels 1001, 1002, 1003, etc.).
Patients withdrawn from the study retain their patient
ID, if already given. New patients are always allotted a
new patient ID. The randomization schedule is stored at
the Institute of Biostatistics at MHH.
Emergency identification of study medication
In the Institute of Biostatistics only the randomization
representative and the medical documentalists have ac-
cess to the randomization lists and the unblinding infor-
mation. The trial statisticians will stay blinded until the
blind data review is successfully completed.
Table 2 Exclusion criteria of the PROHEARING clinical trial
Exclusion criteria
1. Ossification or any other cochlear anomaly that might
prevent complete insertion
of the electrode array, as confirmed by medical examination
and tests including imaging (e.g., digital volume tomography, DVT)
2. Signs of retrocochlear or central origin to hearing impairment as
confirmed by medical
examination and tests including imaging (e.g., DVT)
3. Medical or psychological conditions which contraindicate surgery
(e.g., active middle ear infections, tympanic membrane perforation)
4. Pregnancy or lactation
5. Additional handicaps that would prevent participation in evaluations
6. Contraindications for ACEMg:
hepatopathy (transaminases or γ-GT ≥2 x upper limit of normal,
ULN)
severe renal insufficiency (serum creatinine >2 x ULN)
disposition to kidney stones
iron-storage disease (thalassemia, hemochromatosis, sideroblastic
anemia)
co-medication with vitamin K antagonists
heavy smoking (20 cigarettes per day or more)
7 Current participation in any other clinical trial and/or participation in
another clinical trial
within 30 days before the study begins
ACEMg vitamins A, C, E and magnesium, DVT digital volume tomography, ULN
upper limit of normal
Table 3 List of Soundbites® and Soundbites softgel capsule® components
Component Milligrams per tablet (label claim) Milligrams per daily dose
(6 tablets per day)
Milligrams per softgel
capsule (label claim)
Milligrams per daily dose
(2 softgel capsules per day)
β-carotene 3.0 18 9.0 18
Ascorbic acid 83.33 499.98 250.0 500.0
dl-α-tocopherol acetate 44.5 267 133.5 267
Magnesium 52.5 315 157.5 315
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Emergency envelopes are prepared by the Institute of
Biostatistics and handed out to the investigator. If a pa-
tient is in potential danger and the investigator needs to
know which treatment the patient has received, the pa-
tient’s emergency envelope may be opened. This must be
documented and justified in the electronic Case Report
Form (eCRF) and in the subject’s medical records. Treat-
ment with the study medication must be stopped and all
relevant study staff members are informed.
In case of an unblinding requested by the clinical
pharmacologist, the member of the pharmacovigilance
service will contact one unblinded person responsible
for the randomization at the Institute of Biostatistics via
telephone and specify the ID of the patient to be un-
blinded. The Institute of Biostatistics will send an email
to the clinical pharmacologist with the relevant unblind-
ing information within two workdays.
Dosage/therapy schedule
All patients in the study receive treatment with ACEMg
or placebo for a total of 106 days. Treatment start is on
day 2 preoperatively. The study medication is also taken
at the day of surgery and after surgery it is taken for a
further 103 days (Fig. 1). Medication is administered
twice daily.
Treatment plan
Based on strict inclusion and exclusion criteria eligible
patients for this trial are identified out of the CI candi-
dates routinely screened in the MHH Clinic of Otolaryn-
gology. Informed consent is obtained from all patients
before protocol-specific treatments are carried out. After
preoperative audiological functional testing, eligible pa-
tients take the IMP per os, starting 2 days prior to CI
surgery and continuing for 103 days following surgery.
The follow-up lasts for approximately twelve additional
months post FF.
A short overview of the treatment and follow-up is
given in Table 4.
Study procedures
All study procedures and their relevant performance
dates are listed in the study calendar (Table 5).
Recruitment and screening
The MHH Clinic of Otolaryngology is one of the world’s
largest CI centers. Patients suffering from hearing loss
are transferred to our clinic for further diagnostics and
therapy. Based on the information collected during rou-
tine CI preliminary investigation potential candidates for
the study are asked if they are interested in this study by
a study staff member (approved investigator for recruit-
ment as documented in the delegation log). CI screening
includes a medical examination, pure-tone audiogram
and the Freiburg Speech Test at 65 dB best aided to test
the speech intelligibility. Air-conducted hearing thresh-
olds at the ear to be implanted have to be less or equal
to 85 dB HL at 125, 90 dB HL at 250 Hz and better or
equal than 95 dB HL at 500 Hz. The auditory speech un-
derstanding must be less or equal to 60 %. Before inclu-
sion in this clinical trial, patients have to answer
additional questions about their health and lifestyle. The
inclusion of patients in this clinical trial depends on the
results of these investigations. Only if the patient fulfills
all inclusion and exclusion criteria and agrees to sign the
Informed Consent Document is he recruited for the
study. A quiet office is used for these face-to-face private
interviews. Approved medical doctors will be conducting
introductory meetings with potential subjects.
Audiological tests
All audiological testing is performed in an acoustic insu-
lated chamber. An overview of the tests to be performed
is given in Table 6. Additionally, the list is plotting, on
which study visit which test is performed. Details are ex-
plained in the following section.
Pure-tone audiometry Pure-tone audiometry is per-
formed using a calibrated audiometer according to DIN
Fig. 1 Timeline of the clinical trial PROHEARING. The investigational medicinal product (IMP; ACEMg or placebo) intake starts 2 days
before cochlear implant (CI) surgery and lasts for 103 days after surgery. On days 42 to 46 after surgery the first fitting (FF) takes place.
At months 3, 6, 9 and 12 after FF study visits are performed
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Table 4 Overview of study visits, treatment and follow-up
Study day Procedure What is done? Routine Study
Between 6 months and 2 days
preop
CI screening Including:
Hearing tests Air-conducted and bone-conducted threshold, speech test best
aided (with hearing aids) and unaided
x
Study audiologist evaluates if audiological inclusion criteria for
study are fulfilled
Informing the senior physician
x
Medical talk Results are discussed x
Possibilities are explained: hearing preservation/conventional
electrodes
x
Decision about hearing preservation electrode x
Identification for the study
Passes potential patients to: assistant physician/study nurse/study
audiologist
x
Information about the CI technique x
Introductory meeting and, when indicated, recruitment (hand out
Informed Consent Document)
x
Following In critical cases the patient’s documents are shown to the chief
physician
x
Cost assurance must be checked x
If CI surgery is indicated, the surgery appointment will be made
Imaging (e.g., DVT) x
Between screening and 2 days
preop
Study approval
Patient agrees to Informed Consent Document x
Study audiologist will be informed x
Blood sample For pregnancy test, if necessary x
Blood sample For γ-GT, transaminases, creatinine x
Blood sample Vitamin E baseline detection x
Questionnaire The patients complete the NCIQ x
Imaging (e.g., DVT) x
Pre-decision of electrode length (for study patients FLEX-
electrodes are fixed)
x
Between screening and 3 days
preop
Operation appointment
The appointment for operation is sent to the patient x
Approximately 5 days preop Patient demonstration
All planned surgeries of the coming week are presented x
Overview of the planned study patients, if necessary participating
at the discussion
x
Between 10 and 2 days preop Randomization
Fill out patient inclusion form in web-randomization tool
Inclusion of the patient in the eCRF database
x
Inform the HCTC about patient’s inclusion in the study x
2 days preop Treatment start
Treatment Starting taking IMPs x
1–2 days preop Prefinal diagnostics and
patient information
Patient reception x
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EN 60318 to detect the acoustic hearing threshold in
both ears: the one to be implanted and the contralateral
one.
The test method follows DIN ISO 8253 with head-
phones for air conduction and a headset for bone con-
duction in both ears.
Warble The warble-tone audiometry is the audiometri-
cally determined audiogram of patients supplied with the
device (processor) by single tones in free field. It is mea-
sured with the same audiometer as pure-tone audiometry
and gives feedback about the fitting of the processor
for the CI engineer. The warble tones are frequency-
modulated pure tones which are used to avoid standing
waves. Electric stimulation (ES) and acoustic stimulation
(AS) are measured separately to detect the individual
hearing thresholds with each component of the processor.
Freiburg Speech Test The most commonly used speech
perception test is K.H. Hahlbrock’s word test (1953) de-
scribed as the Freiburg Speech Test (Freiburg Numbers
and Word Test). Hearing loss is declared in percent for
words and decibels for numbers. The test is presented
without additional noise. The Freiburg Speech Test con-
sists of number words, which are double-digit and
mostly four-syllable (10 groups of 10 numbers) and
monosyllabic words (20 groups of 20 words).
Oldenburger Satztest (OLSA) This is an adaptive
sentence test in noise [10] and shall be performed with a
Table 4 Overview of study visits, treatment and follow-up (Continued)
Hearing tests Air-conducted and bone-conducted threshold, speech test best
aided (with hearing aids, if available)
x
Vestibularis, BERA, PT x
Information about the
surgery
x
Day 0 Cochlear implant surgery
Between 1 day preop and day 0 Blood sample Vitamin E blood level x
Surgery The patient has a FLEX-electrode implanted x
1–5 days postop Hearing tests
Hearing tests Air-conducted (if possible) and bone-conducted threshold x
Test tone Technical check of the implant x
Patients return packing of IMPs taken x
Appointment for the first activation x
Usually 4 weeks postop,
depending on wound healing
First Fitting
Hearing tests Air-conducted (if possible) and bone-conducted threshold x
Speech tests in quiet and in noise x x
Fitting Technical check of the implant x
Blood sample Vitamin E blood level x
Questionnaire The patients complete the NCIQ x
Patients return packing of IMPs taken x
Appointment for the 3 months post FF follow-up x
3, 6, 9 and 12 months post-FF
(±14 days each)
Follow-up
Patients return packing of IMPs taken x
Hearing tests Speech tests in quiet and in noise x x
Air-conducted and bone-conducted threshold, (aided threshold) x
Fitting Technical check of the implant x
103 days postop End of IMP intake x
Only month 6 post FF Blood sample Vitamin E blood level x
Only 3 and 12 months post FF Questionnaire The patients complete the NCIQ x
CI cochlear implant, eCRF electronic Case Report Form, DVT digital volume tomography, FF first fitting, HCTC Hannover Clinical Trial Center, IMP investigational
medicinal product, NCIQ Nijmegen Cochlear Implant Questionnaire, postop posoperatively, preop preoperatively
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Table 5 Study calendar
Study
approval
ACEMg
treatment
Period/visit CI screening Baseline Baseline
audiometry
Surgery
Point of time Between
−6 months
and −3 days
−2 days −(1–2)
days
Day 0 Days
1–5
First fitting (FF)
Days
42–46
(±14 days)d
Month 3
after FF
(±14 days)
Month 6
after FF
(±14 days)
Month 9
after FF
(±14 days)
Month 12
after FF
(±14 days)
Assessment
Inclusion/exclusion criteria x
Demographic data (subject identification) x
Medical history x
Concurrent medications x x x x x x x x
Imaging (e.g., DVT) x
Anticipated electrode length x
Adverse event assessmenta x x x x x x x
Physical examinationb x
Aetiology of hearing loss x
Informed consent x
Blood sample (ACEMg) x x x x
Questionnaire (NCIQ) x x x x
Tinnitus Questionnaire x x x x x x x x
Pregnancy test x
Blood sample for γ-GT, transaminases, creatinine x
IMP intakec x x x x x x
Number of returned IMP x x x x x x
Implantation date x
Surgeon x
Implanted electrode length x
Audio processor activation x
Technical check of the implant (impedances) x x x x x x x
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Table 5 Study calendar (Continued)
Audio processor fitting x x x x x
Audiometric test: air and bone conduction (unaided condition) x x x x x x x x
Audiometric test: warble-tone air conduction in free field ES/AS
(if possible)
x x
Speech test: OLSA best aided (like) preoperatively x
Speech test: ES only, AS only
(if available), ES + residual hearing or EAS
(if available) condition
x x x x x
aThe adverse event documentation period for this trial begins upon first administration of the IMP(s) and ends 30 days after the last application of the investigational medical product. In case of continuation of any
adverse event the documentation period will be prolonged until all adverse events are resolved or until the investigator assess the adverse events as “chronic” or “stable”
bThe physical examination includes: medical history, audiometry, otoscopy, imaging (e.g., DVT)
cThe IMP will be taken 2 days preoperatively until 103 days postoperatively
dThis timepoint takes 5 days (from Monday to Friday). All assessments are made only once
ACEMg vitamins A, C, E and magnesium, AS acoustic stimulation, DVT digital volume tomography, EAS electric acoustic stimulation, ES electric stimulation, IMP investigational medicinal product, NCIQ Nijmegen
Cochlear Implant Questionnaire, OLSA Oldenburger Satztest
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fixed noise level and a variable signal (speech) level to
reflect a real-life situation. This test establishes the
speech reception threshold in noise. The speech recep-
tion threshold is defined as 50 % speech reception in
noise and calculated by counting the number of cor-
rectly understood words.
Impedance measurements
To determine the electrode functionality impedance
measurements are performed using the appropriate
measurement system of the relevant implant developer.
Blood samples
Blood is sampled between screening and 2 days pre-
operatively to exclude contraindications and to deter-
mine vitamin E baseline levels. Additional blood samples
are taken 1 day preoperatively or at the day of implant-
ation, at the FF visit 1 month after surgery and 6 months
after the FF.
Serum levels for γ-GT, transaminases and creatinine
To exclude hepatopathy and severe renal insufficiency as
contraindications for ACEMg (see exclusion criteria),
blood samples for γ-GT, transaminases and creatinine
are taken at the screening visit.
Serum pregnancy test If there is no negative pregnancy
test submitted (for women aged between 18 and 50 years;
not necessary for women older than 50 years who are at
least 1 year menopausal) blood samples for pregnancy
tests are taken between the screening appointment and
treatment start (2 days preoperatively) if necessary. The
pregnancy test is accomplished by means of “HCG
STAT” instruction (Roche) and has been standardized
against the 4th International Standard for Chorionic
Gonadotropin from the National Institute for Biological
Standards and Control (NIBSC) code 75/589.
Serum vitamin E level For ACEMg blood level detec-
tion only vitamin E (dl-α-tocopherol) is determined as a
parameter to correlate vitamin serum levels with the
hearing loss during the final data analysis. Blood samples
for ACEMg blood level detection are taken by standard
venipuncture at various timepoints (Table 4).
For the measurement of vitamin E a photometric
detection is performed with the aid of a high-
performance liquid chromatography (HPLC) Complete
Kit (Recipe®).
Questionnaire
The Nijmegen Cochlear Implant Questionnaire (NCIQ),
a quantifiable, self-assessment health-related quality of
life (QoL) instrument for use in CI users is used to
evaluate the subjective scoring of QoL. In this test three
principal domains are distinguished: physical, psycho-
logical and social.
Pharmacovigilance
The EU Clinical Trials Directive 2001/20 provides the
definitions of adverse events (AEs) and reactions used in
this trial. Because the IMP is a composition of vitamins
and magnesium, it is expected that only few of the par-
ticipants will experience AEs. All AEs will be primarily
documented in the patient’s source documents. In
addition to the documentation in the source documents,
AEs will be documented in the eCRF in the following
cases:
 An AE is serious
 An AE leads to discontinuation of IMP intake
Table 6 Audiological tests per study visit. This table plots on which study visit a particular test is performed
Test Condition 1–2 days preop 1–4 days postop 4 weeks postop 3, 6, 9 and 12
months post FF
Pure-tone, air-conduct Unaided X X X X
Pure-tone, air-conduct Unaided-contralateral X X X
Pure-tone, bone-conduct Unaided X X X X
Pure-tone, bone-conduct Unaided-contralateral X X X
OLSA training X X X
OLSA in noise Best aided (like) preop in implantable ear Xa
OLSA in noise EAS or ES + residual hearing X X
OLSA in noise ES and ipsilateral closed ear canal X X
OLSA in noise AS if activated X X
Warble ES X Xb
Warble AS if available X Xb
AS acoustic stimulation, EAS electric acoustic stimulation, ES electric stimulation, OLSA Oldenburger Satztest
aOnly if hearing aids are available
bOnly 3 months post first fitting
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The AE documentation period for this trial begins
upon first administration of the IMP(s) and ends 30 days
after the last application of the IMP. In case of continu-
ation of any AE the documentation period will be pro-
longed until all AEs are resolved or until the investigator
assess the AEs as “chronic” or “stable.”
Documentation of AEs must be performed in a timely
manner on the respective AE Forms in the patient folder
and in the eCRF.
An adverse reaction is an AE which is related to the
administration of the study drugs. If any adverse reac-
tions arise, they will be reported on the AE Form within
the CRF. If a serious adverse event (SAE) thought to be
related with the study drug occurs, reporting will follow
the regulatory requirements and will be reported to the
competent authority and the sponsor within 24 hours of
our becoming aware of the event.
All suspected unexpected serious adverse reactions
(SUSARs) will be the subject of expedited reporting.
Fatal or life-threatening SUSARs must be reported
within 7 days, all other SUSARs need to be reported
within 15 days.
Any pregnancy occurring within the reporting period as
well as significant overdosing must be reported as a SAE.
Sample size calculation
Sample size is feasibility driven as cochlear implantation
with residual hearing is a relatively rare condition. Initial
sample size estimation was based on historical data from
the MHH Department of Otolaryngology with patients
receiving CI electrodes of different lengths. The type-I
error was set at 5 % (two-sided) and sample size was cal-
culated for a power of 80 % using a two-group t test. A
change in hearing thresholds from baseline to 3 months
after FF of 15.6 dB with a standard deviation of 15.5 dB
at 500 Hz has been observed. For the sample size calcu-
lation it has been assumed that the standard deviation is
the same in the placebo and in the active treatment
group and that the mean change in hearing thresholds is
5 dB smaller with ACEMg therapy compared to placebo.
Under these assumptions a required sample size of 150
patients per group was targeted. However, recruitment
has been difficult up to now and a total of 300 patients
cannot be enrolled in a reasonable time frame. The sam-
ple size target was reduced to 70 patients per group in a
recent amendment. The power to detect a relevant 5-dB
treatment effect decreases to approximately 50 % (which
means an increase in the type-II error to 50 %), but a
total of 140 patients should be sufficient to decide in this
phase II trial whether ACEMg offers a promising treat-
ment concept for protection of residual hearing in CI.
The power increases to 80 % if the treatment difference
is in the order of 7.5 dB. No interim analysis will be
performed.
Statistical analysis
The primary analysis is based on the intention-to-treat
(ITT) population consisting of all randomized patients
who took the study medication at least once. The pri-
mary null hypothesis of equal hearing loss in ACEMg
and placebo will be evaluated with an analysis of covari-
ance (ANCOVA) model including the factor treatment
(ACEMg versus placebo), the baseline residual hearing,
surgeon, planned length of electrode and formulation of
medication (chewing pills versus softgel capsules). The
null hypothesis, of no smaller reduction in residual hear-
ing for ACEMg patients, is rejected if the upper bound
of the ANCOVA-derived two-sided 95 % confidence
interval of the difference in change from baseline
(ACEMg minus placebo) is less than 0.
To evaluate the robustness of the estimated treatment
effect, the primary analysis will be repeated based on the
per-protocol population. In addition, the primary object-
ive is evaluated with the nonparametric, stratified Gehan
test as a sensitivity analysis. Moreover, analysis will be
conducted using real length of electrode instead of
planned length of electrode as independent factor.
Secondary analyses will be conducted on the ITT
population and on the per-protocol population as sensi-
tivity analyses. Key secondary analyses include the com-
parison of ACEMg group to placebo in terms of residual
hearing for different frequencies and different timepoints
after surgery. All analyses will be performed in line with
the primary analysis using ANCOVA. Differences in the
treatment effects within patient groups with different
electrode length are evaluated descriptively.
Absolute and relative frequencies of (serious) adverse
events will be listed for each treatment group separately.
Differences will be analyzed in a descriptive manner.
The safety population will be used for analysis.
Extent of study treatment exposure and compliance
To quantify compliance to the study medication, serum
vitamin E levels are measured in all randomized patients
before, during (at surgery and 4 weeks postoperatively)
and after treatment period. Moreover, patients return
their treatment kits to the study site and provide in-
formation on their compliance via a short, self-
administered questionnaire.
Patients under ACEMg treatment are only classified as
compliant (and used for per-protocol analysis):
 If their vitamin E level 4 weeks postoperatively is
≥20 μg/ml
Nevertheless an ACEMg patient will be classified as
noncompliant even though their vitamin E level is
≥20 μg/m if:
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 The patient states in the questionnaire a
noncompliance >50 %, and/or
 The returned treatment kits contains >50 % of the
study medication, whereas missing bottles or blisters
are considered as full bottles or blisters
Patients in the placebo group with postoperative vita-
min E levels ≥20 μg/ml are most likely to be noncompli-
ant to the study procedures, since they agreed in their
informed consent not to use daily multivitamins or other
supplements during the course of the study, but show
vitamin E levels that are unrealistic without vitamin
supplements.
Patients under placebo are classified as noncompliant:
 If their vitamin E level 4 weeks postoperatively is
≥20 μg/ml, and/or
 If the patient states in the questionnaire a
noncompliance >50 %, and/or
 If the returned treatment kits contain >50 % of the
study medication, whereas missing bottles or blisters
are considered as full bottles or blisters
Data handling conventions and missing values
The primary endpoint is residual hearing measured in
decibels for a frequency of 500 Hz by air-conducted
pure-tone audiometry at the implanted ear. If the patient
reaches the upper detection limit of the 500-Hz air-
conducted pure-tone audiometry of 110 dB without
hearing, the measurement is set to 120 dB as the upper
limit of detection + 10 dB. This “upper limit +10” ap-
proach is used in all analyses concerning residual hear-
ing (for all frequencies).
The anticipated drop-out rate is expected to be low in
PROHEARING as patients in the initial phase after CI
are closely followed for clinical reasons. Frequency and
reasons for drop-out will be recorded as far as possible
and will be analyzed in both study arms. Missing values
in the ITT analysis of pure-tone audiometry are replaced
by worst possible value, that means that a missing value
at any follow-up visit is replaced by the respective upper
limit of quantification + 10 dB.
Data management
All study data are collected by study personnel. Data are
entered via an eCRF in a clinical trial database. For each
patient enrolled an eCRF must be completed after the
patient’s visit. This also applies to records for those pa-
tients who fail to complete the study. Only SAEs will be
additionally documented and notified on paper forms.
Verification of the data in the eCRF occurs by moni-
toring as well as via range, validity, and consistency
checks programmed in the system. In certain cases,
queries can be detected by the study software or by an
authorized study staff member. Based on the queries,
the investigator can review and answer the discrepancies
that are found directly in the system. All changes of data
entered in the eCRF can be followed by an audit trail.
A quality control will be performed before the data-
base is closed. This procedure is documented. After the
close-out visit at the study center the access of the inves-
tigator to the eCRF/database is changed to a “read-only”
access (modification of data is no longer possible). After
database closure the investigator and the data manager
can only read the data, they can not change them; the
final data set is transferred to the Institute for Biometry
for statistical analysis of the SAS data.
Patient information/informed consent and data
protection
The investigator is responsible for obtaining the patient’s
written informed consent after adequate explanation of
the aim, study assessments, potential risks, benefits, and
consequences of the study, as well as alternative treat-
ment options. The patient information/informed consent
form has to be signed in duplicate by the patient and the
investigator. One document will be given to the patient,
the other remains in the Trial Investigator File (TIF) at
the trial site. No study procedures are allowed to be con-
ducted until the patient’s written informed consent has
been obtained.
The patient information/informed consent form has to
be revised whenever important new information be-
comes available that may be relevant to the subject’s
consent. The patients have to be informed and asked to
give their consent to continue study participation by
signing the updated form.
All study staff members have to give due consideration
to data protection and medical confidentiality. The col-
lection, transfer, storage and analysis of personal study-
related data are performed pseudonymized according to
national regulations. The declaration of data protection
is contained within the patient information/informed
consent form.
Monitoring and audits/inspections
To ensure compliance with the protocol, to legal and
regulatory requirements applicable for clinical trials and
with the ethical principles of the Declaration of Helsinki
and the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use (ICH) and GCP, monitoring visits are
scheduled to take place during the study. At those regular
monitoring visits, the monitor reviews the eCRF for com-
pleteness and clarity and performs source data verification.
Source data are defined as any printed, optical and elec-
tronic document containing source data (e.g., hospital
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records, laboratory notes, drug accountability records). The
monitor also reviews notification of SAEs and the TIF.
Audits (by the sponsor) and inspections (by regulatory
authorities) may be performed in order to verify that the
clinical study is performed according to the study pr-
otocol as well as to other applicable regulatory require-
ments. The auditor or inspector is independent in
regard to personnel involved in the conduct of this clin-
ical trial. This may occur at any time from start to after
closure of the study.
Generally the sponsor quality manager audits the con-
duct of a clinical trial on a regular basis (determination
of frequency is risk-adapted; usually annually). Inspec-
tions by regulatory authorities happen infrequently and
cannot be foreseen by the investigator or sponsor.
The establishment of a data monitoring committee
(DMC) for this clinical study was not considered neces-
sary by the sponsor as a “non-critical indication where
patients are treated for a relatively short time and the
drugs under investigation are well characterized and
known for not harming patients” (cited from “Guideline
on data monitoring committees,” EMA 27 July 2005) is
being investigated. In addition, safety endpoints are veri-
fied by the monitor during periodic monitoring visits
and reported to the sponsor within the written report
after each visit.
Discussion
The insertion of a CI into the inner ear is to some extent
potentially damaging to the inner ear tissue, which can
affect the endocochlear potential, create oxidative stress,
and initiate proapoptotic pathways associated with direct
injury to, and loss of, hair cells [11]. Even though to our
knowledge the exact mechanisms involved during CI sur-
gery that results in loss of residual hearing are not com-
pletely understood recent findings on caspase activation,
JNK activation, oxidative stress with reactive oxygen spe-
cies, and lipid peroxidation of cellular membranes [12]
give a first hint of possible targets for drug-based therapies
of insertion trauma-related hearing loss.
There is an increasing role for antioxidants in the pro-
tection of residual hearing loss as there is more evidence
that links high levels of oxidative stress to programmed
cell death of the remaining hair cells. Knowledge of the
mechanisms underlying noise-induced hearing loss
(NIHL) and drug-induced hearing loss (DIHL) has led to
the hypothesis that cochlear-implantation-related hear-
ing loss is based on the same pathophysiology. Noise
and ototoxic drugs induce free radical formation in the
inner ear, which up-regulate apoptotic cell-death genes
[13]. If free radical build up is sufficient, cell membranes
are attacked, resulting in necrotic cell death [13].
Some exogenous antioxidants were tested in animal
models and some degree of benefit has being shown against
cisplatin, carboplatin, aminoglycoside, and noise-induced
trauma to the inner ear: D-methionine (D-met [14]); ascor-
bic acid (vitamin C [15]); dl-α-tocopherol (vitamin E [16]);
N-acetylcysteine (NAC [17, 18]). Clinical trials examining
the benefit of antioxidants on hearing loss of different ori-
gins are various and include NAC (ClinicalTrials.gov Iden-
tifier: NCT00552786), NAC+Mg (ClinicalTrials.gov
Identifier: NCT01727492) or ACEMg (ClinicalTrials.gov
Identifier: NCT00808470), which has been evaluated for
the treatment of NIHL. NAC (ClinicalTrials.gov Identifier:
NCT02094625) has been tested for the prevention of
cisplatin-induced hearing loss or sodium thiosulfate to pre-
vent carboplatin- [19] or cisplatin-induced hearing loss
(ClinicalTrials.gov Identifier: NCT01369641; ClinicalTrials.-
gov Identifier: NCT00716976; ClinicalTrials.gov Identifier:
NCT02281006). Prevention of drug-induced ototoxicity is
being tested by NAC treatment (ClinicalTrials.gov Identi-
fier: NCT01131468). But, to our knowledge, only one study
has addressed hearing loss associated with electrode inser-
tion trauma and cochlear implantation. In this study the re-
searchers were able to demonstrate benefit with NAC
treatment [17]. This benefit only pertained to the high fre-
quencies of the basal turn and did not extend significantly
to low-frequency hearing located in the apical section of
the cochlea [17]. Unfortunately, delivery of NAC to the
round window prior to implantation caused a slight in-
crease in hearing thresholds and greater amounts of osteo-
neogenesis, which may preclude its use locally in the
protection of residual hearing [17]. However, there have
been no randomized controlled trials to investigate
antioxidant effects on CI electrode-insertion-related
hearing loss. The study protocol of this clinical trial
allows controlling of all parameters influencing re-
sidual hearing after cochlear implantation. Performing
all surgeries and patient follow-up at one study side
leads to maximum consistency in diagnostics and
therapy by there being less variability in surgery and
audiological testing techniques and fitting. This ap-
proach will allow a better detection of the influence
of ACEMg on residual hearing in CI patients.
The dosage of vitamin C (magnesium ascorbate; 500 mg),
magnesium (magnesium citrate, magnesium ascorbate,
magnesium stearate; 315 mg), vitamin E (dl-α-tocopherol
acetate; 267 mg), and β-carotene (18 mg) administered in
this placebo-controlled trial was chosen to find the correct
balance between a potential therapeutic effect and the sug-
gested tolerable upper intake level: the maximum level of
total chronic daily intake of a nutrient (from all sources)
judged to be unlikely to pose a risk of adverse health effects
to humans [20].
If the hypothesis that decreasing free radicals with this
formulation of micronutrients will preserve residual
hearing in CI patients is correct, then these patients will
benefit from better hearing sensation.
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Trial status
The PROHEARING trial is ongoing, with 51 patients re-
cruited as of June 2015. The last patient out is expected to
be in July 2018.
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